Immune Design closes $49 mln Series C funding round
Immune Design, a biotechnology company, has closed a $49 million Series C funding round, which includes an upfront investment of $32.5 million and the right of the investor syndicate to inject another $16.5 million as the program progresses. Financing was led by The Column Group, new investor Topspin Partners and existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investments. In addition, Sanofi-Genzyme BioVentures joined as a new investor.
30 October 2013•4 mins read
